Guardant Health, Inc. (GH)

18,88 +0,30 (+1,61%) Börsenschluss: 04:00PM EDT

Guardant Health, Inc.

3100 Hanover Street
Palo Alto, CA 94304
United States
855 698 8887
https://guardanthealth.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 1.768

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Helmy Eltoukhy Ph.D.	Co-Founder, Co-CEO & Chairman	11,59k	N/A	1980
Dr. AmirAli Talasaz Ph.D.	Co-CEO & Director	26,41k	N/A	1980
Mr. Michael Bell	Chief Financial Officer	819,27k	N/A	1969
Ms. Darya Chudova	Chief Technology Officer	715,66k	N/A	1974
Dr. Craig Eagle M.D.	Chief Medical Officer	844,86k	N/A	1967
Mr. Christopher Freeman	Chief Commercial Officer	826,27k	N/A	1974
Mr. Kumud Kalia	Chief Information Officer	N/A	N/A	1966
Mr. John G. Saia	Chief Legal Officer & Corporate Secretary	627,18k	N/A	1973
Ms. Jennifer Higgins	Senior Vice President of Public Affairs	N/A	N/A	N/A
Ms. Terilyn Juarez Monroe	Chief People Officer	N/A	N/A	1967

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Corporate Governance

Guardant Health, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 1, Vorstand: 7, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.